Abstract
Dear Editor,
We read with great interest the article by Malaguarnera et al. (1) in this issue of Hepatitis monthly, in which the safety and efficacy of rosuvastatin plus interferon and ribavirin were evaluated in a randomized controlled trial. Sustained viral response was observed in 40% of the standard-care group and 51% of the triple-therapy group, and this was associated with improvement of steatosis and fibrosis without causing side effects. Despite the importance of this study, we think that the clinical implications extracted from this study deserve further evaluation. In particular, we question some components of the study design.
We read with great interest the article by Malaguarnera et al. (1) in this issue of Hepatitis monthly, in which the safety and efficacy of rosuvastatin plus interferon and ribavirin were evaluated in a randomized controlled trial. Sustained viral response was observed in 40% of the standard-care group and 51% of the triple-therapy group, and this was associated with improvement of steatosis and fibrosis without causing side effects. Despite the importance of this study, we think that the clinical implications extracted from this study deserve further evaluation. In particular, we question some components of the study design.
Keywords
References
-
1.
The references are available in the PDF file.
Copyright
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.